Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/181335
Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
S-(+) enantiomer of ibuprofen (IBU) dexibuprofen (DXI) is known to be more potent than its R-(−) form and exhibits many advantages over the racemic mixture of IBU such as lower toxicity, greater clinical efficacy, and lesser variability in therapeutic effects. Moreover, DXI potential has been recently advocated to reduce cancer development and prevent the development of neurodegenerative diseases in addition to its anti-inflammatory properties. During the last decade, many attempts have been made to design novel formulations of DXI aimed at increasing its therapeutic benefits and minimizing the adverse effects. Therefore, this article summarizes pharmacological information about DXI, its pharmacokinetics, safety, and therapeutic outcomes. Moreover, modified DXI drug delivery approaches are extensively discussed. Recent studies of DXI prodrugs and novel DXI nanoformulations are analyzed as well as reviewing their efficacy for ocular, skin, and oral applications. View Full-Text Keywords: dexibuprofen; NSAIDs; enantiomer; drug delivery; prodrugs
Subject (English)
Citation
Citation
SÁNCHEZ-LÓPEZ, E. (Elena) and GLISZCZYŃSKA, Anna. Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations. Pharmaceutics. 2021. Vol. 13, num. 3, pags. 414. ISSN 1999-4923. [consulted: 6 of June of 2026]. Available at: https://hdl.handle.net/2445/181335